{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:07:45Z","timestamp":1778803665496,"version":"3.51.4"},"reference-count":53,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007683","name":"Nihon University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007683","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jiac.2026.102983","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:40:12Z","timestamp":1777581612000},"page":"102983","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk prediction for linezolid-induced thrombocytopenia and exposure-guided safety optimization"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2297-2287","authenticated-orcid":false,"given":"Saki","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7967-2947","authenticated-orcid":false,"given":"Yasuhiro","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2026.102983_bib1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40262-017-0601-x","article-title":"Clinical pharmacokinetics and pharmacodynamics of oxazolidinones","volume":"57","author":"Roger","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jiac.2026.102983_bib2","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/bcp.13262","article-title":"Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients","volume":"83","author":"Tsuji","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2026.102983_bib3","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1128\/AAC.01185-10","article-title":"Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients","volume":"55","author":"Sasaki","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2026.102983_bib4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijantimicag.2014.05.010","article-title":"Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients","volume":"44","author":"Matsumoto","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2026.102983_bib5","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/jac\/dkz374","article-title":"Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: findings from a monocentric, prospective, open-label, interventional study","volume":"74","author":"Cojutti","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2026.102983_bib6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/345744","article-title":"Linezolid for the treatment of multidrug-resistant, gram positive infections: experience from a compassionate-use program","volume":"36","author":"Birmingham","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2026.102983_bib7","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijantimicag.2006.04.017","article-title":"High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency","volume":"28","author":"Lin","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2026.102983_bib8","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/jac\/dks153","article-title":"Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients","volume":"67","author":"Pea","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2026.102983_bib9","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/jac\/dkt133","article-title":"High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia","volume":"68","author":"Nukui","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2026.102983_bib10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/jcpt.12762","article-title":"Linezolid-induced thrombocytopenia increases mortality risk in intensive care unit patients, a 10 year retrospective study","volume":"44","author":"Kim","year":"2019","journal-title":"J Clin Pharm Therapeut"},{"key":"10.1016\/j.jiac.2026.102983_bib11","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1001\/jama.285.10.1291","article-title":"Linezolid and reversible myelosuppression","volume":"285","author":"Green","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jiac.2026.102983_bib12","first-page":"237","article-title":"Bleeding complications in immune thrombocytopenia","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"Suppl 2","key":"10.1016\/j.jiac.2026.102983_bib13","first-page":"ii17","article-title":"Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections","volume":"51","author":"MacGowan","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2026.102983_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00605-19","article-title":"Reappraisal of linezolid dosing in renal impairment to improve safety","volume":"63","author":"Crass","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2026.102983_bib15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1086\/498509","article-title":"High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease","volume":"42","author":"Wu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2026.102983_bib16","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1128\/AAC.01694-12","article-title":"Risk factors for a low linezolid trough plasma concentration in acute infections","volume":"57","author":"Morata","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2026.102983_bib17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijantimicag.2010.02.019","article-title":"Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction","volume":"36","author":"Matsumoto","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2026.102983_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13082380","article-title":"Linezolid-associated thrombocytopenia: assessment of risk factors in patients without hemato-oncologic diseases","volume":"13","author":"Thabit","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jiac.2026.102983_bib19","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.htct.2019.07.004","article-title":"A retrospective cohort study to screen linezolid-induced thrombocytopenia in adult patients hospitalized in the midwestern region of Brazil","volume":"42","author":"Lima","year":"2020","journal-title":"Hematol Transfus Cell Ther"},{"key":"10.1016\/j.jiac.2026.102983_bib20","first-page":"1136","article-title":"Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects","volume":"29","author":"Slatter","year":"2001","journal-title":"Drug Metab Dispos"},{"issue":"Suppl 4","key":"10.1016\/j.jiac.2026.102983_bib21","first-page":"iv7","article-title":"Linezolid pharmacokinetics and pharmacodynamics in clinical treatment","volume":"66","author":"Dryden","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2026.102983_bib22","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1093\/jac\/dkad191","article-title":"Establishment and validation of a risk prediction model incorporating concentrations of linezolid and its metabolite PNU142300 for linezolid-induced thrombocytopenia","volume":"78","author":"Xu","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2026.102983_bib23","article-title":"A nomogram incorporating linezolid and metabolite concentrations for predicting linezolid induced thrombocytopenia in patients with renal impairment","volume":"14","author":"Zhao","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jiac.2026.102983_bib24","article-title":"Evaluating the impact of linezolid metabolites: PNU-142300 and PNU-142586 on the development of linezolid-induced thrombocytopenia in adult patients","author":"Sakurai","year":"2025","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2026.102983_bib25","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s11096-014-9961-6","article-title":"Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients","volume":"36","author":"Hirano","year":"2014","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.jiac.2026.102983_bib26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2026.102983_bib27","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.amjopharm.2004.12.005","article-title":"Pharmacokinetics in older persons","volume":"2","author":"Cusack","year":"2004","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.jiac.2026.102983_bib28","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ijantimicag.2016.08.023","article-title":"Therapeutic drug management of linezolid: a missed opportunity for clinicians?","volume":"48","author":"Cattaneo","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2026.102983_bib29","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/ejhpharm-2022-003258","article-title":"Development and validation of a risk prediction model for linezolid-induced thrombocytopenia in elderly patients","volume":"31","author":"Qin","year":"2024","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.jiac.2026.102983_bib30","doi-asserted-by":"crossref","first-page":"486","DOI":"10.17826\/cumj.1638509","article-title":"Assessment of linezolid-induced thrombocytopenia in older patients: reflections from a palliative care unit","volume":"50","author":"Ganida\u011fl\u0131","year":"2025","journal-title":"Cukurova Medical Journal"},{"key":"10.1016\/j.jiac.2026.102983_bib31","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jiac.2019.05.025","article-title":"Pharmacokinetics, toxicity and clinical efficacy of linezolid in Japanese pediatric patients","volume":"25","author":"Ogami","year":"2019","journal-title":"J Infect Chemother : Official J Japan Soc Chemotherapy"},{"key":"10.1016\/j.jiac.2026.102983_bib32","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/pan.13272","article-title":"What is the best size predictor for dose in the obese child?","volume":"27","author":"Anderson","year":"2017","journal-title":"Paediatr Anaesth"},{"key":"10.1016\/j.jiac.2026.102983_bib33","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1007\/s00228-024-03740-3","article-title":"Evaluation of pharmacokinetic target attainment and hematological toxicity of linezolid in pediatric patients","volume":"80","author":"Abouelkheir","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2026.102983_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.710099","article-title":"A regression model to predict linezolid induced thrombocytopenia in neonatal sepsis patients: a ten-year retrospective cohort study","volume":"13","author":"Duan","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jiac.2026.102983_bib35","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jiac.2014.08.017","article-title":"Linezolid dosage in pediatric patients based on pharmacokinetics and pharmacodynamics","volume":"21","author":"Matsumoto","year":"2015","journal-title":"J Infect Chemother : Official J Japan Soc Chemotherapy"},{"key":"10.1016\/j.jiac.2026.102983_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.926711","article-title":"Relationship between linezolid exposure and the typical clinical laboratory safety and bacterial clearance in Chinese pediatric patients","volume":"13","author":"Huo","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jiac.2026.102983_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214037","article-title":"Effects of a rifampicin pre-treatment on linezolid pharmacokinetics","volume":"14","author":"Okazaki","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jiac.2026.102983_bib38","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2169\/internalmedicine.54.2292","article-title":"Treatment of mediastinitis due to methicillin-resistant Staphylococcus aureus in a renal dysfunction patient undergoing adjustments to the linezolid dose","volume":"54","author":"Tsuji","year":"2015","journal-title":"Intern Med"},{"key":"10.1016\/j.jiac.2026.102983_bib39","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.diagmicrobio.2014.01.012","article-title":"Reduction of linezolid-associated thrombocytopenia by the dose adjustment based on the risk factors such as basal platelet count and body weight","volume":"79","author":"Niwa","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jiac.2026.102983_bib40","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3855\/jidc.10859","article-title":"Risk factors for linezolid-associated thrombocytopenia and negative effect of carbapenem combination","volume":"13","author":"Kaya","year":"2019","journal-title":"J Infect Dev Ctries"},{"key":"10.1016\/j.jiac.2026.102983_bib41","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1056\/NEJM199809103391107","article-title":"Thrombopoietin","volume":"339","author":"Kaushansky","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2026.102983_bib42","first-page":"282","article-title":"Managing thrombocytopenia associated with cancer chemotherapy","volume":"29","author":"Kuter","year":"2015","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jiac.2026.102983_bib43","first-page":"2301","article-title":"Pharmacodynamic model of topotecan-induced time course of neutropenia","volume":"7","author":"Zamboni","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jiac.2026.102983_bib44","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/bcpt.13123","article-title":"Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases","volume":"124","author":"Choi","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.jiac.2026.102983_bib45","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s11096-021-01342-y","article-title":"Risk factors for linezolid-induced thrombocytopenia in adult inpatients","volume":"44","author":"Han","year":"2022","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.jiac.2026.102983_bib46","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s10096-013-2041-3","article-title":"Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients","volume":"33","author":"Dong","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jiac.2026.102983_bib47","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/j.xphs.2021.02.014","article-title":"Classification tree analysis based on machine learning for predicting linezolid-induced thrombocytopenia","volume":"110","author":"Takahashi","year":"2021","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.jiac.2026.102983_bib48","first-page":"415","article-title":"Use of Japanese big data from electronic medical records to investigate risk factors and identify their high-risk combinations for linezolid-induced thrombocytopenia","volume":"79","author":"Inoue","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2026.102983_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/ph16111575","article-title":"Derivation and clinical utility of safety targets for linezolid-related adverse events in drug-resistant tuberculosis treatment","volume":"16","author":"Keutzer","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jiac.2026.102983_bib50","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ijantimicag.2013.02.020","article-title":"Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections","volume":"41","author":"Cattaneo","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2026.102983_bib51","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jfma.2020.06.011","article-title":"Impact of high plasma concentrations of linezolid in Taiwanese adult patients- therapeutic drug monitoring in improving adverse drug reactions","volume":"120","author":"Cheng","year":"2021","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jiac.2026.102983_bib52","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/00365548.2011.608712","article-title":"Correlation between serum linezolid concentration and the development of thrombocytopenia","volume":"44","author":"Hiraki","year":"2012","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jiac.2026.102983_bib53","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40262-016-0463-7","article-title":"Clinical determinants of target non-attainment of linezolid in plasma and interstitial space fluid: a pooled population pharmacokinetic analysis with focus on critically ill patients","volume":"56","author":"Minichmayr","year":"2017","journal-title":"Clin Pharmacokinet"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X26000814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X26000814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:12:40Z","timestamp":1778800360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X26000814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1341321X26000814"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2026.102983","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk prediction for linezolid-induced thrombocytopenia and exposure-guided safety optimization","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2026.102983","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102983"}}